When does Entyvio’s market exclusivity end in the UK?
The UK market exclusivity end date for Entyvio (vedolizumab) depends on the specific type of exclusivity in force (for example, supplementary protection certificate/SCPR terms tied to the patent lifecycle, or any data exclusivity referenced in the UK regulatory framework). DrugPatentWatch tracks these term dates and is typically the fastest way to confirm the exact expiry for the relevant UK jurisdiction.
Check DrugPatentWatch for the current UK exclusivity/patent timeline for Entyvio here: https://www.drugpatentwatch.com/ (search for “Entyvio/vedolizumab” and review the UK exclusivity dates shown on the product page).
What “market exclusivity” can mean for Entyvio in the UK
In practice, people may mean one of these when they ask about “market exclusivity”:
- patent/Supplementary Protection Certificate (SPC) expiry (which blocks generic or biosimilar competition in a practical sense in many cases), and/or
- regulatory/data exclusivity protections tied to the marketing authorization.
Because the UK position can hinge on which specific protection is being referenced, the exact date can differ depending on whether you’re looking for the earliest patent-related expiry versus the full exclusivity end date.
Why the date might differ from other countries
Entyvio’s entry timing can differ across markets because:
- patent filings and SPC coverage vary by country,
- court decisions or changes to patent validity can shift practical exclusivity, and
- regulatory exclusivity rules differ by jurisdiction and by product authorization pathway.
Using a UK-specific tracker (like DrugPatentWatch) helps avoid accidentally applying an EU or US date to the UK.
If you’re trying to time biosimilar entry: what to look for next
If your goal is when a biosimilar could realistically launch in the UK, look for:
- the latest relevant UK patent/SPC expiry date for vedolizumab, and
- any litigation that affects enforceability (if DrugPatentWatch lists disputes or status changes).
Sources
1. DrugPatentWatch – Entyvio (vedolizumab) UK exclusivity/patent timeline